Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$937b Graphic](https://lunarcrush.com/gi/w:26/t:$937b.png) $937b

Johnson & Johnson's Q3 results and raised sales outlook are driving positive sentiment, while a $9.37B crypto liquidation event is causing concern.

### About $937b
A cryptocurrency.  

### Insights [#](/topic/$937b/insights)
- $937b engagements is up XXXXX% from the previous month.

### Engagements: XX [#](/topic/$937b/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$937b/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$937b/time-series/interactions.tsv)  
**Current Value**: XX  
**Daily Average**: XXXXX  
**1 Week**: XXXXXX +178%  
**1 Month**: XXXXXX +1,621%  
**1-Year High**: XXXXXXX on 2025-07-23  
**1-Year Low**: X on 2025-07-01  

| Social Network | X  |
| -------------- | -  |
| Engagements    | XX |
  

  
  
### Mentions: X [#](/topic/$937b/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$937b/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$937b/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1 Month**: XX +325%  
**1-Year High**: XX on 2025-07-24  
**1-Year Low**: X on 2025-05-05  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$937b/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$937b/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$937b/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $937b in the last XX hours which is down XX% from X in the previous XX hours
**Daily Average**: X  
**1 Month**: XX +250%  
**1-Year High**: XX on 2025-07-24  
**1-Year Low**: X on 2025-05-05  

The most influential creators that mention $937b in the last XX hours

| Creator                                          | Rank | Followers | Posts | Engagements |
| -------                                          | ---- | --------- | ----- | ----------- |
| [@GlobalStatsXX](/creator/twitter/GlobalStatsXX) | X    | XXXXXX    | X     | X           |

[View More](/list/creators/$937b/100)
  
  
### Sentiment: % [#](/topic/$937b/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$937b/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$937b/time-series/sentiment.tsv)  
**Current Value**: %  
**Daily Average**: XX%  
**1-Year High**: XXX% on 2025-06-24  
**1-Year Low**: X% on 2025-07-23  

**Top assets mentioned**
In the posts about $937b in the last XX hours

[Johnson & Johnson (JNJ)](/topic/johnson-johnson)
[Toyota Motor Corporation (TM)](/topic/$tm)
[Sumitomo Mitsui Financial Group, Inc (SMFG)](/topic/$smfg)
[FAST RETAILING UNSP/ADR (FRCOY)](/topic/frcoy)
[Johnson & Johnson (JNJ)](/topic/$jnj)
[Innovative Solutions & Support (ISSC)](/topic/$issc)

**Top topics mentioned**
In the posts about $937b in the last XX hours

[johnson johnson](/topic/johnson-johnson), [stocks healthcare](/topic/stocks-healthcare), [stocks consumer cyclical](/topic/stocks-consumer-cyclical), [$tm](/topic/$tm), [$2512b](/topic/$2512b), [$smfg](/topic/$smfg), [$8309t](/topic/$8309t), [frcoy](/topic/frcoy), [$9983t](/topic/$9983t), [$9434t](/topic/$9434t), [$2139b](/topic/$2139b), [mitsubishi](/topic/mitsubishi), [$8316t](/topic/$8316t), [stocks financial services](/topic/stocks-financial-services), [stocks banks](/topic/stocks-banks), [sony](/topic/sony), [$8306t](/topic/$8306t), [$8058t](/topic/$8058t), [hitachi](/topic/hitachi), [nintendo](/topic/nintendo), [$6758t](/topic/$6758t), [$1794b](/topic/$1794b), [$1749b](/topic/$1749b), [$6501t](/topic/$6501t), [$1359b](/topic/$1359b), [$8053t](/topic/$8053t), [$8031t](/topic/$8031t), [$1030b](/topic/$1030b), [$969b](/topic/$969b), [$7974t](/topic/$7974t), [$967b](/topic/$967b), [keyence](/topic/keyence), [$6861t](/topic/$6861t), [$jnj](/topic/$jnj), [eps](/topic/eps), [$2399b](/topic/$2399b), [$issc](/topic/$issc), [$30b](/topic/$30b), [$29b](/topic/$29b), [$20b](/topic/$20b), [$8b](/topic/$8b), [$63b](/topic/$63b), [$240b](/topic/$240b), [$515b](/topic/$515b), [$2376b](/topic/$2376b), [$934b](/topic/$934b), [$24b](/topic/$24b), [robust](/topic/robust)

### Top Social Posts [#](/topic/$937b/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Johnson & Johnson Raises 2025 Sales Outlook After Strong Q3 Results Johnson & Johnson reported Q3 2025 sales of $24B (+6.8% YoY) and adjusted EPS of $XXXX (+15.7%) driven by robust performance across Innovative Medicine and MedTech segments. 📈 Full-year 2025 reported sales guidance raised to $93.7B with adjusted EPS reaffirmed at $XXXXX. 🚀 Highlights: Oncology growth led by DARZALEX CARVYKTI RYBREVANT + LAZCLUZE TREMFYA receives additional FDA approvals including for subcutaneous ulcerative colitis treatment Strong MedTech performance in cardiovascular (Abiomed Shockwave) surgical vision"  
[X Link](https://x.com/stellanewslife/status/1979595014637588858) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T17:06Z XXX followers, XX engagements


"Johnson & Johnson Q3 2025 delivered steady growth alongside active portfolio moves. - Sales came in at $23.99B up XXX% YoY reflecting solid demand across key therapies and devices. - Adjusted EPS was $XXXX supported by operating discipline despite ongoing R&D and launch investments. - For 2025 management reaffirmed guidance with a sales midpoint of $93.7B and EPS outlook maintained signaling confidence in the trajectory. - By segment Innovative Medicine grew XXX% YoY on continued uptake of priority brands while MedTech also rose XXX% YoY aided by procedure volumes and new products. - On the"  
[X Link](https://x.com/provue_ai/status/1978760600902885879) [@provue_ai](/creator/x/provue_ai) 2025-10-16T09:51Z XXX followers, XXX engagements


"$JNJ J&J is -XXX% this morning. 🔹 EPS: $XXXX vs. $XXXX est. ✅ 🔹 Revenue: $23.76B vs. $23.99B est. ✅ Key takeaways: 🔸 Innovative med rev: +7% YoY 🔸 MedTech rev: +7% YoY 🔸 Plans to split Orthopaedics into standalone business 🔸 FY rev outlook: $93.7B ($93.4B prior)"  
[X Link](https://x.com/CmgVenture/status/1978073516705509498) [@CmgVenture](/creator/x/CmgVenture) 2025-10-14T12:20Z 11.1K followers, XXX engagements


"Johnson & Johnson $JNJ Q3-25. Results: 📊 Adj. EPS: $XXXX 🟢 💰 Revenue: $24.0B 🟢 📈 Net Income: $5.15B 🔎 Strong pipeline progress and product approvals drove XX% jump in net income; 2025 sales outlook raised to $93.7B"  
[X Link](https://x.com/Earnings_Time/status/1978045505977327996) [@Earnings_Time](/creator/x/Earnings_Time) 2025-10-14T10:29Z 12.3K followers, 14K engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$937b Graphic $937b

Johnson & Johnson's Q3 results and raised sales outlook are driving positive sentiment, while a $9.37B crypto liquidation event is causing concern.

About $937b

A cryptocurrency.

Insights #

  • $937b engagements is up XXXXX% from the previous month.

Engagements: XX #


Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXXXX
1 Week: XXXXXX +178%
1 Month: XXXXXX +1,621%
1-Year High: XXXXXXX on 2025-07-23
1-Year Low: X on 2025-07-01

Social Network X
Engagements XX

Mentions: X #


Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1 Month: XX +325%
1-Year High: XX on 2025-07-24
1-Year Low: X on 2025-05-05

Social Network X
Mentions X

Creators: X #


Creators Line Chart
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $937b in the last XX hours which is down XX% from X in the previous XX hours Daily Average: X
1 Month: XX +250%
1-Year High: XX on 2025-07-24
1-Year Low: X on 2025-05-05

The most influential creators that mention $937b in the last XX hours

Creator Rank Followers Posts Engagements
@GlobalStatsXX X XXXXXX X X

View More

Sentiment: % #


Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: %
Daily Average: XX%
1-Year High: XXX% on 2025-06-24
1-Year Low: X% on 2025-07-23

Top assets mentioned In the posts about $937b in the last XX hours

Johnson & Johnson (JNJ) Toyota Motor Corporation (TM) Sumitomo Mitsui Financial Group, Inc (SMFG) FAST RETAILING UNSP/ADR (FRCOY) Johnson & Johnson (JNJ) Innovative Solutions & Support (ISSC)

Top topics mentioned In the posts about $937b in the last XX hours

johnson johnson, stocks healthcare, stocks consumer cyclical, $tm, $2512b, $smfg, $8309t, frcoy, $9983t, $9434t, $2139b, mitsubishi, $8316t, stocks financial services, stocks banks, sony, $8306t, $8058t, hitachi, nintendo, $6758t, $1794b, $1749b, $6501t, $1359b, $8053t, $8031t, $1030b, $969b, $7974t, $967b, keyence, $6861t, $jnj, eps, $2399b, $issc, $30b, $29b, $20b, $8b, $63b, $240b, $515b, $2376b, $934b, $24b, robust

Top Social Posts #


Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"Johnson & Johnson Raises 2025 Sales Outlook After Strong Q3 Results Johnson & Johnson reported Q3 2025 sales of $24B (+6.8% YoY) and adjusted EPS of $XXXX (+15.7%) driven by robust performance across Innovative Medicine and MedTech segments. 📈 Full-year 2025 reported sales guidance raised to $93.7B with adjusted EPS reaffirmed at $XXXXX. 🚀 Highlights: Oncology growth led by DARZALEX CARVYKTI RYBREVANT + LAZCLUZE TREMFYA receives additional FDA approvals including for subcutaneous ulcerative colitis treatment Strong MedTech performance in cardiovascular (Abiomed Shockwave) surgical vision"
X Link @stellanewslife 2025-10-18T17:06Z XXX followers, XX engagements

"Johnson & Johnson Q3 2025 delivered steady growth alongside active portfolio moves. - Sales came in at $23.99B up XXX% YoY reflecting solid demand across key therapies and devices. - Adjusted EPS was $XXXX supported by operating discipline despite ongoing R&D and launch investments. - For 2025 management reaffirmed guidance with a sales midpoint of $93.7B and EPS outlook maintained signaling confidence in the trajectory. - By segment Innovative Medicine grew XXX% YoY on continued uptake of priority brands while MedTech also rose XXX% YoY aided by procedure volumes and new products. - On the"
X Link @provue_ai 2025-10-16T09:51Z XXX followers, XXX engagements

"$JNJ J&J is -XXX% this morning. 🔹 EPS: $XXXX vs. $XXXX est. ✅ 🔹 Revenue: $23.76B vs. $23.99B est. ✅ Key takeaways: 🔸 Innovative med rev: +7% YoY 🔸 MedTech rev: +7% YoY 🔸 Plans to split Orthopaedics into standalone business 🔸 FY rev outlook: $93.7B ($93.4B prior)"
X Link @CmgVenture 2025-10-14T12:20Z 11.1K followers, XXX engagements

"Johnson & Johnson $JNJ Q3-25. Results: 📊 Adj. EPS: $XXXX 🟢 💰 Revenue: $24.0B 🟢 📈 Net Income: $5.15B 🔎 Strong pipeline progress and product approvals drove XX% jump in net income; 2025 sales outlook raised to $93.7B"
X Link @Earnings_Time 2025-10-14T10:29Z 12.3K followers, 14K engagements

$937b
/topic/$937b